Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

2307 results about "Polythylene glycol" patented technology

Polyethylene glycol 3350 is used to treat occasional constipation. Polyethylene glycol 3350 is in a class of medications called osmotic laxatives. It works by causing water to be retained with the stool.

Stabilized Glycosaminoglycan Preparations and Related Methods

Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.)
Owner:S K PHARMA INC

High molecule bonding adriamycin medicine, nano capsule and preparation thereof

The invention provides a macromolecule bonding adriamycin medicine, a nanometer capsule and a preparation method thereof. The bonding medicine is bonded by a block copolymer of poly ethylene glycol-polylactic acid and adriamycin. Firstly, the block copolymer of poly ethylene glycol-polylactic acid is acquired by ring-opening polymerization of aliphatic cyclic esters with poly ethylene glycol, solvent and catalyst being in existence; then a carboxyl end group is transformed by a hydroxyl-terminated; and then with a condensing agent being in existence, the carboxyl end group carries out amidation reaction with the adriamycin; thus acquiring the macromolecule adriamycin bonding medicine. The bonding medicine has amphiphilic property, thus being able to self assembly to prepare the nanometer capsule with a core-shell structure in the water solution. The adriamycin is wrapped inside the capsule to play a role of isolation and protection, which overcomes the deficiencies of short circulation time in vivo, large dosage and severe allergic reaction existing in the current adriamycin preparation. In addition, the nanometer particles are expected to congregate in the blood circulation through the so-called 'enhanced infiltration and retention effect', so as to improve the targeting action of the adriamycin on the tumor location.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI

Crosslinked hydrogel copolymers

InactiveUS20050020734A1Easy to adaptAvoids hydrophobicityPolyesterGlycidyl methacrylate
The present invention relates to crosslinked polymers, synthesized through ring-opening polymerization of ethylenically unsaturated epoxides, in combination with α-hydroxy acids using a hydrophilic macroinitiator, such as poly(ethylene glycol), to form substituted copolymers having ethylenically unsaturated functionality randomly distributed along the polyester polymer backbone. That copolymer is subsequently crosslinked to form a hydrogel network. More particularly, the present invention relates to the synthesis of biodegradable poly(α-hydroxy acid-co-glycidyl methacrylate)-block-poly(ethylene glycol)-block-poly(α-hydroxy acid-co-glycidyl methacrylate) copolymers, which are subsequently crosslinked to form hydrogel networks. The invention also relates to the use of these hydrogel networks in various applications, in particular, for the controlled release of drugs and proteins.
Owner:ALKERMES INC

Low-viscosity opacifiers free from anionic surface-active agents

The invention relates to wax-based opacifier preparations containing (a) at least one amphoteric surfactant, (b) at least one fatty acid partial glyceride, (c) at least one fatty acid polyglycol ester and optionally (d) a polyol, with the proviso that the ratio by weight of (a) to (b) is between 10:1 and 4:1 and the ratio by weight of (b) to (c) is between 1:1 and 5:1 and the preparations are free from anionic surfactants.
Owner:COGNIS DEUT GMBH & CO KG

Preparation of polycarboxylic acid water reducing agent for prefabricated part

ActiveCN101475664AShorten the activity gapPromote polymerizationSide chainPersulfate
The invention discloses a preparation method for a polyocarboxy acid water reducing agent for precast units, which belongs to the field of water reducing agent. Under the action of a persulphate initiator, methoxypolyethylene glycol acrylate, acrylic acid, unsaturated sulfonic acid or a salt monomer b thereof, unsaturated amide or a salt monomer c thereof are copolymerized in an aqueous solution; a terminator is used to process the rest initiator of the reaction at a later polymerization stage; and finally alkaline solution is used for neutralization and the water reducing agent is obtained. The methoxypolyethylene glycol with high polymerization degree is introduced as a grafting side chain, thereby making the prepared water reducing agent effectively shorten the concrete coagulation time without reducing the concrete initial fluidity and improving the concrete compression strength. The early strength type polyocarboxy acid high performance water reducing agent can be widely applied to the construction of various concrete projects with a low temperature or early strength requirements, in particular to the low energy consumption production process of precast concrete units. The water reducing agent has wide generalization space.
Owner:HUIZHOU JIANKE IND

Chelate derivatives as protectors against tissue injury

Derivatives useful in the protection of living organisms against damage due to free radical reactions derived from methoxypolyethylene glycols (MPEG), which are modified by chemically attaching chelating groups in an amide or amine linkage to the nonmethyl end of the polymer. Such chelating groups include ethylene-diamine tetraacetic acid (EDTA), diethylene triamine pentaacetic acid (DTPA), and ethylene glycol aminoethyl ether tetraacetic acid (EGTA), and pharmacologically acceptable salts or esters thereof.
Owner:EASTERN VIRGINIA MEDICAL SCHOOL

Mono-functionalized polyethylene glycol with nitrogen atom branched center and its preparation method and biologically-relevant matter

The invention discloses a mono-functionalized polyethylene glycol with a nitrogen atom branched center and its preparation method and biologically-relevant matter. The mono-functionalized polyethylene glycol with a nitrogen atom branched center is shown in the general formula (1). The polyethylene glycol-modified biologically-relevant matter is shown in the general formula (2). X1 and X2 represent alkyl containing 1-20 carbon atoms, n1 and n2 are integers of 2-2000, n3 is an integer of 1-2000, L1, L2 and L3 represent connection groups stably existing under the conditions of light, heat, enzyme, redox, acidic or alkaline condition, R represents a functional group or is in a protected form, D represents a biologically-relevant matter, Z1 represents a connection group, and L4 represents residue formed by a reaction of R and the biologically-relevant matter. The branched polyethylene glycol with the nitrogen atom center can interact with a substrate easily so that the substrate protection based on polyethylene glycol is promoted, the state of the substrate in the human body can be effectively improved and a prospect is wide.
Owner:XIAMEN SINOPEG BIOTECH

High molecule adriamycin bonding medicine nano capsule with targeting function and preparation thereof

The invention provides a nanometer capsule of a macromolecule adriamycin bonding medicine with a targeting function and a preparation method thereof. The nanometer capsule is mixed assembled with two block copolymers of poly ethylene glycol-polylactic acid, wherein the polylactic acid chain end of one block copolymer is connected with adriamycin, with a molar ratio of 98-70 percent in the nanometer capsule, while the poly ethylene glycol chain end of the other block copolymer is connected with lactose, with a molar ratio of 2-30 percent in the nanometer capsule. The adriamycin connected with the polylactic acid chain end is located in the capsule inner core, which is double protected by polylactic acid and poly ethylene glycol and has sustained release function; while the lactose connected with the poly ethylene glycol chain end is located in the outer layer of the capsule, which has targeting function and leads the nanometer capsule preferentially enter the cells carrying the lactose receptors.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI

Degradable unsaturated polyesteramide resin and synthesis method thereof

InactiveCN101168595ADo not pose a hazardReduce alkalinityPolyethylene glycolAdipic acid
The invention adopts a melt polycondensation method. A few of monomers of C2-5 aliphatic dibasic alcohol, diethylene glycol, polyglycol, fumaric acid, maleic anhydride, lactic acid, glycolic acid, ethanolamine, C2 to C12 aliphatic diamine, glutamic acid, lysine, glycine, etc. are taken as basic materials to be synthesized to obtain non toxic unsaturated polyester-amide resin with adjustable degradation rate and lower cost; wherein, the partial fumaric acid or maleic anhydride can be replaced with phthalic anhydride, isophthalic acid, or adipic acid. The resin yearns for being used as matrix resin of medical bone internal fixation material, tissue engineering scaffold material, bone tissue temporary substitutes, environmental protection type bonding agent, environmental protection type fiberglass reinforced plastics, environmental protection type coating material, disposable tableware, packing material, shopping bags, disposable bags, drug coating or capsule, drug delivery (controlled-release) material, agricultural mulching films, etc., and can be recovered to be utilized.
Owner:HUNAN UNIV

Neutral blockage removing agent composition used for oil recovery formation in oilfield and preparation method thereof

The invention relates to a neutral blockage removing agent composition used for an oil recovery formation in an oilfield. The neutral blockage removing agent composition is prepared from the following raw materials in parts by weight: 30-36 parts of disodium polyepoxysuccinicate, 18-25 parts of sodium gluconate, 2-3 parts of polyethylene glycol, 2-4 parts of triethanolamine, 9-12 parts of ethyl lactate, 7-10 parts of fatty alcohol polyoxyethylene ether sodium sulfate, 8-12 parts of amino acid sodium, 10-15 parts of activated attapulgite, 0.1-0.2 part of vanadium pentoxide, 5-7 parts of lipase, 5-8 parts of sorbitan fatty acid ester, 15-18 parts of P-hydroxy sodium sulfonate, 3-7 parts of tert-butyl hydroperoxide and 0.1-0.3 part of diethylene glycol monolaurate. The neutral blockage removing agent composition has high blockage removing speed, is neutral, is free of corrosion and can quickly dissolve material scales, asphalt sediment scales, carbonate scales, silicate scales and the like generated by an ASP flooding system; waste liquid for blockage removal can be degraded and does not need to be discharged onto the ground to be subjected to sewage treatment, the formation in the oilfield is cleaned to remove the blockage, no corrosion, dead angle, precipitation or secondary well blockage is generated, and the blockage removal time does not exceed 24 hours.
Owner:GANSU HEIMA PETROCHEM ENG

Polydopamine and polyethylene glycol vitamin E succinate-modified mesoporous silica nanoparticle as well as preparation method and application thereof

The invention provides a polydopamine and polyethylene glycol vitamin E succinate-modified mesoporous silica nanoparticle as well as a preparation method and application thereof. Specifically, the preparation method of the polydopamine and polyethylene glycol vitamin E succinate-modified mesoporous silicon dioxide nanoparticle comprises the following steps: 1) dissolving mesoporous silicon dioxide and a drug into a solvent, reacting to be complete and separating to obtain a drug-loaded mesoporous silica initial nanoparticle; 2) adding the initial nanoparticle into a solution, adding dopamine hydrochloride, reacting to be complete and separating to obtain a drug-loaded polybutadiene-wrapped mesoporous silica nanoparticle; 3) adding the polybutadiene-wrapped mesoporous silica nanoparticle into a weak base aqueous solution, adding polyethylene glycol 1000 vitamin E succinate, reacting to be complete and separating to obtain a tumor targeting mesoporous silica nanoparticle. The nanoparticle provided by the invention is simple in preparation method, free from pollution and good in biocompatibility and biodegradability, and has a treatment effect on a lung cancer.
Owner:SHENZHEN GRADUATE SCHOOL TSINGHUA UNIV

Green preparation method of slow-release polycarboxylic-acid high-performance water reducing agent

The invention relates to a green preparation method of a slow-release polycarboxylic-acid high-performance water reducing agent, which comprises the following steps: firstly, dissolving unsaturated polyethenoxy ether in water, adding an oxidant solution, and evenly stirring; then, respectively and dropwisely adding a reducer/chain-transfer agent mixed solution and a comonomer solution, and polymerizing; and finally, adding an alkaline regulator to neutralize and age the solution, thereby obtaining the slow-release polycarboxylic-acid high-performance water reducing agent. In the invention, hydrogen on the terminal hydroxyl group of the original unsaturated polyethenoxy ether is substituted by an allyl group containing unsaturated bond, so that the terminal group of methoxypolyethylene glycol is converted from the original active hydroxyl group into the inert methoxy group at present; and thus, the byproducts of the copolymerization product are greatly reduced, and the molecular weight distribution is narrow, so that the synthesized water reducing agent has the advantages of high water reduction rate and slump resistance. The redox system with low activation energy is used for initiating the monomer copolymerization, so that the polymerization can be implemented at normal temperature, thereby implementing the production of the product by a no heat source method, simplifying the production equipment and lowering the energy consumption and cost.
Owner:NANJING RUIDI HIGH TECH

Preparation method for high-slump-retention polycarboxylate water reducer

InactiveCN103450411AIncreased steric hindranceSolve problems such as difficult pumpingMeth-Ptru catalyst
The invention discloses a preparation method for a high-slump-retention polycarboxylate water reducer. The preparation method comprises the following steps of: esterifying methoxylpolyethylene glycol monomethyl ethers with different molecular weights with methacrylic acid and a mixed polymerization inhibitor for a period of time under the action of a catalyst and at a certain temperature, then adding allyl alcohol in one time, further esterifying in the same conditions to obtain an esterified macromonomer MP containing crosslinking monomer allyl methacrylate; then performing aqueous solution polymerization on the MP, unsaturated sulfonate, (meth)acrylate unsaturated monomers and a chain transfer agent in a low-temperature condition and within a redox initiation system; and finally adding caustic soda liquid to neutralize, so as to obtain the polycarboxylate water reducer with a certain concentration. The high-slump-retention polycarboxylate water reducer prepared by the preparation method disclosed by the invention is a high-performance water reducer which is prepared at a low temperature by virtue of a molecular structure design, as well as is high in slump retention, excellent in dispersing performance, good in adaptability, simple in process, pollution-free, low in energy consumption, and easy to realize industrialized production.
Owner:KZJ NEW MATERIALS GROUP CO LTD

Thermogelling polymer blends for biomaterial applications

Thermogelling polymers are described containing poly (n-isopropyl acrylamide). Solutions of this polymer, copolymers or mixtures of the polymer with a second polymer such as poly(ethylene glycol), poly (vinyl pyrrolidone) or poly(vinyl alcohol) are liquids at room temperature and solids at body temperature. Thus, also provided are methods of implanting a hydrogel into a mammal by injecting the solution as a liquid at a temperature below body temperature into a selected site in the mammal at a temperature below body temperature, which then undergoes thermal phase transition to form a solid hydrogel in situ in the body as the implant warms to body temperature. Methods for using these thermal gelling materials in various applications including nucleus pulposus replacement / augmentation, wound care, disk replacement, cartilage replacement, joint replacement, surgical barriers, gastrointestinal devices, cosmetic and reconstructive surgery, and breast enlargement are also provided.
Owner:SYNTHES USA +1

Highly effective polypeptide for inhibiting angiogenesis, physical chemistry modifying method and application thereof

The invention relates to a high-performance angiogenesis inhibitor and a production method, which belongs to the field of the biological engineering pharmaceutical technology or protein polypeptide drugs. The invention designs a high-performance angiogenesis inhibitor RGD-ED with integrin compatibility, the inhibitor contains angiogenesis inhibition polypeptide isoleucine-valine-arginine-arginine-alanine-aspartate-arginine-alanine-alanine-valine-proline, and one or two ends of the inhibitor are respectively connected with polypeptides containing arginine-glycin-aspartate sequence. The RGD-ED of the invention can be synthesized. By the method of genetic engineering, the invention also expresses one of RGD-Eds in escherichia coli or other eukaryotic cells, and the RGD-ED is obtained by carrying out the separation, dissolution and renaturation of inclusion body protein and separation and purification by ion exchange chromatography. All the polypeptide sequences of the invention are modified by Polyethylene Glycol (PEG), heparin, dextran, polyvinylpyrrolidone (PVP), polyglycol-poly (amino acid) copolymer, palmitic acid, colominic acid and liposome, which includes liposome (REV), drying liposomal (DRV) and multivesicular liposome (Mvl). In vivo and in vitro experiments, the synthetic polypeptide sequence, product of genetic engineering and modified product of the invention can notably increase the effects of inhibiting the growth of endothelial cells, inhibiting angiogenesis and resisting tumor of the present angiogenesis inhibitors, and moreover, the high-performance angiogenesis inhibitor can be used as a drug curing solid tumors and rheumatoid arthritis.
Owner:CHINA PHARM UNIV

Prepn process of microcapsule with included anticancer medicine

The present invention discloses the preparation process of microcapsule with included anticancer medicine. The process adopts colloid particle containing polyelectrolyte as template, assembles polyelectrolytes with dislike charges via layer-by-layer self-assembling to the surface of colloid particle, and dissolves or decomposes the colloid particle to obtain hollow polymer microcapsule containing polyelectrolyte. The microcapsule has wall micro structure and thickness capable of being regulated precisely in nanometer size, and the contained polyelectrolyte can interact with the medicine so as to include the medicine into the microcapsule. The included medicine has controllable release speed. Introducing polyelectrolyte with grafted polyglycol to the surface of the microcapsule can raise the biocompatibility of the microcapsule. The process of the present invention is simple, feasible and repeatable, and suitable for inclusion and controllable release of various kinds of water soluble anticancer medicine.
Owner:ZHEJIANG UNIV

Method for extracting squalene by using camellia oleosa seeds as raw materials and tea oil and squalene soft capsules

The invention discloses a method for extracting squalene by using camellia oleosa seeds as raw materials and tea oil and squalene soft capsules and relates to the technical field of biomedicine. The extraction method comprises the following process flows of material preparation, grinding, leaching, concentration, methyl esterification, complexant-borax reaction, macroporous resin chromatographic separation and purification, concentration, extraction, washing, concentration, preparation of squalene crude oil and supercritical carbon dioxide extraction, so that squalene essential oil with the squalene content of more than or equal to 80 percent is obtained. The tea oil and squalene soft capsules are prepared from the following raw materials in percentage by weight: 87 to 90 percent of squalene essential oil with the squalene content of more than or equal to 80 percent, 3 to 5 percent of polyethylene glycol 400, 2 to 3 percent of beewax and 2 to 5 percent of phospholipid. The raw material resources are wide. The prepared tea oil and squalene soft capsules not only can be used for medicine, but also can be used for food therapy, are particularly suitable for administration of treatment and food therapy of patients suffering from hepatitis, fatty liver, acute and chronic inflammation, tumor, chemotherapy, diabetes mellitus and cardio-cerebrovascular disease and have no toxic or side effects.
Owner:李文东
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products